Concepedia

R. Brachmann

RB

Statistics

Publications

9

Citations

725

H-Index

9

Active since

1995

Affiliations

University of Colorado Denver(Current)

Vanderbilt-Ingram Cancer Center

Johns Hopkins University

Fox Chase Cancer Center

USC Norris Comprehensive Cancer Center

R. Brachmann is an author at University of Colorado Denver specializing in medicine, molecular oncology, and pharmacology.

Publications per year

1995–2016

9

Publications

9

Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.

Marc Vidal, R. Brachmann, Ali Fattaey et al. · Proceedings of the National Academy of Sciences · 1996 · 430 citations · Full text

, , +14

Dominant-negative p53 mutations selected in yeast hit cancer hot spots.

R. Brachmann, Marc Vidal, Jef D. Boeke · Proceedings of the National Academy of Sciences · 1996 · 161 citations · Full text

, , +13

Functional Census of Mutation Sequence Spaces: The Example of p53 Cancer Rescue Mutants

Samuel A. Danziger, S. Joshua Swamidass, Jue Zeng et al. · IEEE/ACM Transactions on Computational Biology and Bioinformatics · 2006 · 42 citations · Full text

, , +9

A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

Benjamin Besse, Jean‐Charles Soria, Carlos Gomez‐Roca et al. · Journal of Clinical Oncology · 2011 · 21 citations

, , +17

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Wells A. Messersmith, S. Cohen, Safi Shahda et al. · Annals of Oncology · 2016 · 20 citations · Full text

, , +11

1–5 of 9